Arkolith/Insider Trading/TRIL/Form 4

Parsons James T.

Chief Financial OfficerTrillium Therapeutics Inc. (TRIL) · full profile →Form 4 · filed Nov 19, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
0 non-derivative · 8 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 17, 2021Disposed to issuer(D)30K—$00
Nov 17, 2021Disposed to issuer(D)30K—$00
Nov 17, 2021Disposed to issuer(D)24K—$00
Nov 17, 2021Disposed to issuer(D)36K—$00
Nov 17, 2021Disposed to issuer(D)6K—$00
Nov 17, 2021Disposed to issuer(D)60K—$00
Nov 17, 2021Disposed to issuer(D)180K—$00
Nov 17, 2021Disposed to issuer(D)95K—$00

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-21-141747) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML